Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection

Share Article

Bernstein Liebhard LLP is representing plaintiffs in testosterone lawsuits involving AndroGel and similar Low T therapies, and the outcomes of bellwether trials may provide insight into how juries will rule in similar cases.

Free Case Review
Our Firm is representing a number of testosterone lawsuit plaintiffs whose claims are pending in the federal litigation, and we are pleased that the proceeding is moving ahead with bellwether trials.

The federal court overseeing hundreds of testosterone lawsuits (http://www.testosteronelawsuithub.com/) has amended the Case Management Order governing case selection for bellwether trials involving AbbVie, Inc.’s AndroGel testosterone gel. The Amended Order which was issued in the U.S. District Court, Northern District of Illinois on May 29, 2015, directs the parties to submit a Proposed Case Management Order to the Court by August 10, 2015 that outlines parameters and the process for selecting AbbVie-only plaintiffs in two tiers of cases: 1) clotting injuries, and 2) cardiovascular injuries such as heart attacks. The Order stipulates that only cases for which a plaintiff’s fact sheet has been completed on or before June 15, 2015 are eligible to be selected as bellwether candidates. The first of six AbbVie-only bellwether trials will begin on October 31, 2016. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 254)

“Our Firm is representing a number of testosterone lawsuit plaintiffs whose claims are pending in the federal litigation, and we are pleased that the proceeding is moving ahead with bellwether trials. In multidistrict litigations, the outcomes of bellwether trials are intended to provide insight into how juries might rule in similar cases,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free case reviews to men who may have been harmed by low testosterone therapy medications.

Testosterone Litigation
According to court documents, the federal testosterone litigation began to grow shortly after the U.S. Food & Drug Administration (FDA) announced in January 2014 that it was investigating the cardiovascular risks potentially associated with Low T therapy.* The FDA has since ordered the manufacturers of prescription testosterone treatments to modify their labels with information regarding a potential association with an increased risk of heart attack and stroke, and to revise language pertaining to approved indications so that it is clear the drugs haven’t been proven safe and effective for treating symptoms associated with age-related drops in testosterone.

Since the multidistrict litigation was established in June 2014, more than 1,500 testosterone treatment lawsuits have been filed in the Northern District of Illinois, all of which allege that use of testosterone replacement therapies are associated with an increased risk of heart attacks, strokes, and other dangerous cardiovascular events. In addition, plaintiffs accuse the drugs’ manufacturers of wrongly marketing their products as safe and effective treatments for low libido, fatigue and other age-related symptoms, even though the medications have never been approved for this purpose.

Men who allegedly experienced dangerous cardiovascular complications due to their use of low testosterone treatments may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm, FDA, January 31, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website